A phase III randomized study of cisplatin (NSC 119875) and Taxol (paclitaxel) (NSC 125973) with interval secondary cytoreduction versus cisplatin and paclitaxel in patients with suboptimal stage III and IV epithelial ovarian carcinoma
Phase of Trial: Phase III
Latest Information Update: 20 May 2010
At a glance
- Drugs Cisplatin (Primary) ; Paclitaxel (Primary)
- Indications Ovarian cancer
- Focus Therapeutic Use
- 20 May 2010 Actual end date (March 2010) added as reported by ClinicalTrials.gov.
- 12 Sep 2005 New trial record.